Skip to content
lifestyle.newsblaze.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
July 30, 2026
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
July 23, 2026
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
July 21, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
July 9, 2026
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
July 1, 2026
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
May 26, 2026
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
May 18, 2026
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
May 18, 2026
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 7, 2026
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
May 6, 2026
1
2
3
Next Page
→